Aciclovir foam - Foamix
Alternative Names: AcycloFoam; Acyclovir foam - FoamixLatest Information Update: 13 Mar 2020
Price :
$50 *
At a glance
- Originator Foamix
- Class Antivirals; Eye disorder therapies; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in Israel (Topical, Foam)
- 02 May 2013 Preclinical development is ongoing in Israel